Out now! The August issue of JCF is live. Catch up on the latest research and insights in heart failure. See what’s inside 👉 https://onlinejcf.com/current #HeartFailure #Cardiology #HeartFailureResearch

The future of women's cardiovascular care starts with today's research. Submit your work to JCF's Focus Issue: The New Frontier of Heart Function in Women. 📅 Deadline: 9/15/26 https://bit.ly/4xQkPSR #WomensHeartHealth #CallForPapers

How reliable is urine sodium concentration during continuous IV diuresis? This Brief Report found substantial temporal variability in urine sodium despite stable loop diuretic infusions, raising questions about its role in monitoring diuretic response. 🔗 https://bit.ly/4wKoG2A

New science alert! Do AF, diabetes, or obesity change the benefits of aspirin withdrawal after HM3 LVAD?💖 This ARIES-HM3 analysis says no. Bleeding decreased without increases in stroke or thrombosis, even in these higher-risk subgroups.🩸 🔗 bit.ly/4gbLxhI

Hear from the guest editors leading The New Frontier of Heart Function in Women as they share their excitement for this upcoming focus issue. 📅 Submissions open through Sept. 15th: bit.ly/4fC1NZh #WomensHeartHealth #HeartFailure #CallForPapers

🫀🤖 Digital twins may help transform HF care from reactive to anticipatory! This JCF Perspectives article explores how patient-specific computational models or "digital twins" could enable earlier detection of instability and more personalized care. 🔗 bit.ly/3TMBHKp

How great is the burden of ATTR-CM? 🫀 In this study using the GWTG-HF registry, patients with ATTR-CM had higher HF readmission rates and greater healthcare costs, despite similar adjusted mortality. Earlier diagnosis and treatment remain critical! 🔗 bit.ly/3RhHBCH

Can interatrial shunts help HFpEF? This State-of-the-Art Review revisits atrial shunt therapy, highlighting how phenotyping, invasive exercise hemodynamics & pulmonary vascular assessment may identify responders while avoiding harm in nonresponders. 🔗 bit.ly/45pzqY5

Call for Papers 📃 JCF invites research examining cardiovascular health from adolescence through healthy aging for our upcoming Focus Issue: The New Frontier of Heart Function in Women. 📅 Deadline: 9/15/26 https://bit.ly/4xQkPSR #WomensHeartHealth #CallForPapers

Can we detect worsening HF before symptoms develop?📡❤️ A novel personalized congestion score derived from an IVC sensor predicted worsening HF events w/92.6% sensitivity & correlated with NT-proBNP levels. Early detection may enable more proactive HF management. bit.ly/44HJTOp

Could sleep apnea be a key driver of adverse outcomes in HFpEF?❤️‍🩹 In a PARAGON-HF analysis, patients with SA had greater LV remodeling, worse BiV strain & 57% ⬆️ risk of HFH or CV death. SA may represent an important, modifiable HFpEF phenotype. onlinejcf.com/article/S107...

How is vericiguat being used in real-world HFrEF care? ❤️‍ In a study of >5,100 US patients following a worsening HF event, only ~36% reached the target 10 mg dose. Patients already receiving robust GDMT were more likely to achieve target dosing. 💊📊 🔗 onlinejcf.com/article/S107...

🫀 The July edition of JCF is here! Featuring the latest perspectives and studies on heart failure and patient care. 🔗 Read the full issue: https://onlinejcf.com/current

📣 Call for Papers JCF is accepting submissions for our focus issue: The New Frontier of Heart Function in Women Research spanning the female lifespan, from reproductive health to HFpEF, prevention, and heart failure is encouraged. 📅 Submit by 9/15/26 https://bit.ly/4xQkPSR #WomensHeartHealth

Can LVADs do more than support circulation? 🫀 This JCF Ignite! article explores whether LVAD-mediated unloading can promote reverse remodeling and myocardial recovery, and whether some patients might benefit from LVAD therapy as a bridge to regeneration. ❤️‍🩹 🔗 https://bit.ly/3S0UHEj

How should palliative care fit into advanced HF care? 💙 The HeartPal program embedded palliative care directly within an advanced heart disease service, resulting in earlier referrals, more GoC discussions, fewer late referrals & reduced in-hospital deaths. 🫀 🔗 bit.ly/3S4btlS

🚨HF-CS is now more common than AMI-CS. This State-of-the-Art Review examines how microaxial flow pumps are reshaping HF-CS care through LV unloading, prolonged support, hemodynamic-guided management, and bridge-to-recovery/transplant strategies. 🫀📊 🔗 https://bit.ly/4ez3oye

🚨 What is the optimal MAP target in AMI-CS? This meta-analysis found no mortality benefit with higher MAP targets vs lower targets. 📊 The findings challenge a "higher is better" approach & highlight the need for individualized perfusion goals. ❤️‍🩹 🔗 https://bit.ly/4vL6dSW

Not all cardiogenic shock is the same!🚨 In the CSWG Registry, patients with HF-CS treated with femoral IABP had ⬇️ mortality, ⬆️ rates of native heart 🫀 survival & more frequent bridging to heart replacement therapy than those with AMI-CS. 🔗 https://bit.ly/4uqv50Y

Can hemodynamic trends help identify 🫀recovery during tMCS? In the UNLOADERS-PVAD Registry, pts supported with VA-ECMO+mAFP demonstrated distinct improvements in CO & functional indices during ECMO weaning. Serial hemodynamics may help guide recovery assessment. 📊 🔗 https://bit.ly/4vGJN5b

📢 Call for Papers Focus Issue: The New Frontier of Heart Function in Women Guest Editors Drs. Anuradha Lala, Martha Gulati, Novi Yanti Sari, and Diana de Oliveira-Gomes will lead this issue, publishing in February '27. Categories & topic areas: https://bit.ly/4vjovuq 🗓 Submit by Sept. 15!

We are proud of the progress reflected in this year’s Impact and Impact Factor of 9.9, but even more proud of what all of this represents. 🎉 A heartfelt THANK YOU to our entire JCF Family. Your engagement as authors, reviewers, readers, and mentors continues to drive this collective success.

🫀 Infiltrative & inflammatory cardiomyopathies share common pathways of dysfunction Advanced imaging is shifting from structure → biology. Probing inflammation, microvascular dysfunction, and energetics to refine diagnosis and guide precision HF care. 📊 🔗 https://bit.ly/4v2Oi9I

Last call! 🚨 Submissions close today for JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture. Don’t miss the opportunity to contribute at this defining moment in HF care. 🫀 https://bit.ly/4kJl5gf #HeartFailure #AIinHealthcare #CallForPapers

Can AI improve detection of infiltrative & inflammatory cardiomyopathies? Emerging data (strongest in amyloidosis) suggest roles in detection & risk stratification, but most evidence remains retrospective and biased. AI may augment (not replace) clinical care. 🫀💻 https://bit.ly/4uvE0Ps

What's new in heart failure research? Find out in the June edition of JCF, featuring expert perspectives advancing our understanding of heart failure and informing patient care. Read the full issue: https://onlinejcf.com/current

In ATTR-CM, acoramidis increased serum TTR and reduced CV death/hospitalization in ATTRibute-CM. Early rises in TTR were linked to lower risk, suggesting sTTR may be a useful biomarker of treatment response. 🫀🧪 https://bit.ly/4dPjwKD

Time is running out to submit to JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture. If your work advances responsible innovation in HF care, now is the time to contribute. ⌛ 🗓️ Deadline: May 10, 2026 https://bit.ly/4kJl5gf #HeartFailure #AIinHealthcare

In HELIOS-B, vutrisiran slowed renal decline in ATTR-CM: fewer ≥40% eGFR drops vs placebo (12.7% vs 21.2%). Benefits on CV outcomes were consistent across kidney function, even in advanced CKD. Improves not just CV outcomes, but has renal benefits! 🫀🧪 https://bit.ly/3Q2hhf1

Cardiac sarcoidosis: beyond steroids? The REPAIR-CS trial is testing rilonacept (IL-1 blockade) added to standard therapy, with FDG-PET inflammation as the primary endpoint—marking a shift toward targeted, mechanism-based treatment. 🫀 🔗 https://bit.ly/3RijCTs